Handling Class Action Claims for Clients Injured by Blood Thinners
Many people suffering from atrial fibrillation and similar conditions take blood-thinning medications, known as anticoagulants, to reduce the risk of blood clots, strokes, and heart attacks. In recent years, pharmaceutical companies introduced a new generation of blood thinners, including Xarelto and Pradaxa. Unlike traditional blood thinner, the new drugs do not require dietary restrictions or regular blood tests, making them more convenient for patients.
Despite the benefits of anticoagulants like Xarelto and Pradaxa, many users have suffered severe and even life-threatening effects. Mass tort claims exist involving numerous plaintiffs who sustained injuries or lost loved ones due to the new blood thinners. If Xarelto or Pradaxa caused you injuries, call the Benner Law Firm to discuss your rights today.
Harm Caused by Xarelto and Pradaxa
Blood thinners decrease the blood’s clotting abilities. If a user suffers an injury or undergoes surgery, they can suffer a major bleeding event because the blood will not clot as usual. Doctors have an antidote for warfarin that will stop bleeding when administered to patients. There is no known antidote for the new generation of blood thinners, however, and it can be exceedingly difficult or impossible to stop a bleeding event in users.
Many Pradaxa or Xarelto users have required extensive medical care and recovery time after a bleeding event. Patients face costly medical bills, lost income, and more due to the serious risks of these dangerous drugs. Some families lose loved ones if major bleeding events cannot be stopped. Pharmaceutical manufacturers should be held fully liable for all of these losses.
Consult with Our San Diego Mass Tort Lawyer for Free Today
Mass tort pharmaceutical claims can be complicated. At the Benner Law Firm, we represent patients who suffered injuries and incurred losses due to Xarelto or Pradaxa. Contact us online or call 619.595.6795 to discuss a class action blood thinner claim today.